ClinicalTrials.Veeva

Menu

Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy (VALENTINE)

Seoul National University logo

Seoul National University

Status

Completed

Conditions

Uterine Leiomyoma

Treatments

Drug: Vasopressin

Study type

Interventional

Funder types

Other

Identifiers

NCT04874246
2011-107-1174

Details and patient eligibility

About

The purpose of this study is to compare the effect of the concentration of vasopressin, which is used as a method for reducing blood loss in robot-assisted laparoscopic myomectomy.

Full description

This study is to compare the effect of the concentration of vasopressin, which is used as a method for reducing blood loss in robot-assisted laparoscopic myomectomy. We would like to evaluate the feasibility and validity of this study for future Phase III randomized clinical trials through this preliminary randomized assignment study.

Uterine fibroids are the most common tumors in women, and uterine myomectomy, which is performed as a treatment for them, is basically a high risk of bleeding and blood transfusion. A common method to reduce intraoperative bleeding is to inject diluted vasopressin into the subserosal areas of the fibroids. However, no proper level of vasopressin dilution has been determined so far, so we want to determine an effective dilution concentration of vasopressin that can minimize side effects through this clinical trial.

Enrollment

39 patients

Sex

Female

Ages

19 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Informed consent
  • Age: 19-60 year-old women
  • Plan of myomectomy for uterine leiomyomas
  • Leiomyoma Subclassification System 2-7 (robot-assisted laparoscopic myomectomy is possible)
  • American Society of Anesthesiologists Physical Status classification 1 or 2
  • A person who understands the contents of the clinical trial, is cooperative with the trial, and is judged to be able to participate until the end of the study

Exclusion criteria

  • Pregnancy or breastfeeding
  • A single diameter of uterine leiomyoma is greater than 12 cm or more or multiple leiomyomas with more than five
  • Suspicious disease of uterine malignancy
  • Patient with has a history of pelvic surgery (cesarean section, myomectomy, etc.) and is expected to have severe pelvic adhesion
  • A person who is hypersensitive or contraindicated to vasopressin
  • A person who is hypersensitive or contraindicated to tranexamic acid
  • Considered as inappropriate by the researcher's judgment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

39 participants in 3 patient groups

Diluted Vasopressin Group 1
Active Comparator group
Description:
During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 50 ml of normal saline to make a total of 100 ml) was injected before uterine serosal incision.
Treatment:
Drug: Vasopressin
Diluted Vasopressin Group 2
Active Comparator group
Description:
During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 200 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
Treatment:
Drug: Vasopressin
Diluted Vasopressin Group 3
Active Comparator group
Description:
During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 400 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
Treatment:
Drug: Vasopressin

Trial contacts and locations

1

Loading...

Central trial contact

Eun Ji Lee, MD; Hee Seung Kim, MD/PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems